Skip to Content

Unituxin Approval History

FDA Approved: Yes (First approved March 10, 2015)
Brand name: Unituxin
Generic name: dinutuximab
Dosage form: Injection
Company: United Therapeutics Corporation
Treatment for: Neuroblastoma

Unituxin (dinutuximab) is a chimeric monoclonal antibody used for the treatment of pediatric neuroblastoma.

Development History and FDA Approval Process for Unituxin

DateArticle
Mar 10, 2015Approval FDA Approves Unituxin (dinutuximab) for Pediatric High-Risk Neuroblastoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide